T-cell receptor (TCR) recognizing neoantigen peptide–HLA class II complex (TCR-neoantigen-HLA-II)

The T-cell receptor (TCR) on CD4+ T cells that recognizes neoantigen peptide–HLA class II complexes is a pivotal mediator of the adaptive immune response against cancer (Tran et al., 2014). Neoantigens are unique, tumor-specific antigens arising from non-synonymous mutations, making them highly specific targets that avoid central tolerance and minimize off-target effects on healthy tissue (Sahin & Türeci, 2018). While CD8+ T cells are the primary effectors in many immunotherapies, CD4+ T cells recognizing HLA class II-restricted neoantigens are essential for a robust and sustained anti-tumor response, providing necessary help for CD8+ T cell recruitment and persistence, and in some cases, exerting direct cytotoxic activity (Alspach et al., 2019; Kreiter et al., 2015). Therapeutic interventions focusing on this target include the development of adoptive TCR-T cell therapies, where T cells are genetically modified to express neoantigen-specific TCRs, and personalized neoantigen vaccines designed to prime and expand these T cell populations in vivo (Rosenberg & Restifo, 2015). Identifying and targeting these complexes is a cornerstone of precision oncology, although challenges such as HLA polymorphism, low neoantigen expression, and the immunosuppressive tumor microenvironment must be addressed to optimize clinical efficacy (Tran et al., 2014; Alspach et al., 2019).

Other names

Neoantigen-specific T-cell receptorMHC class II-restricted TCRCD4+ neoantigen-specific TCRTumor-specific TCRNeoantigen-specific CD4+ TCR

Recognition of tumor-specific mutations (neoantigens) presented by HLA class II molecules, leading to CD4+ T-cell activation, cytokine release, and orchestration of anti-tumor immunity (Tran et al., 2014; Alspach et al., 2019).